SymBiosis LLC
16
54M
10
3
0.38
1
- Areas of investment
Investments analytics
Analytics
- Total investments
- 16
- Lead investments
- 3
- Exits
- 1
- Follow on index
- 0.38
- Investments by industry
- Biotechnology (15)
- Therapeutics (8)
- Life Science (8)
- Health Care (7)
- Medical (7) Show 9 more
- Investments by region
-
- United States (16)
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Avg. valuation at time of investment
- 2M
- Group Appearance index
- 0.81
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Ensoma | 16 May 2023 | Biotechnology, Genetics, Therapeutics | Early Stage Venture | 50M | United States, Massachusetts, Boston |
| Genomic Prediction | 31 Jan 2019 | Biotechnology, Pharmaceutical | Seed | 4M | United States, New Jersey, New Brunswick |
| Micronoma | 12 Aug 2020 | Biotechnology, Health Care, Health Diagnostics, Life Science | Seed | 3M | United States, California, San Diego |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.